{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-102795","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2026-08-28T12:30:17+00:00","discovered_at":"2026-08-28T12:35:17.372674+00:00","generated_at":"2026-08-28T12:35:32.037030+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aprea expands IP portfolio to 28 issued, 30 pending patents for oncology programs","bullets":["Total portfolio now 28 issued and 30 pending patents across WEE1 and ATR inhibitor programs.","WEE1 program: 2 pending US apps, 1 provisional, 2 granted non-US patents (Australia, Korea), 12 pending non-US; expiry 2047.","ATR program: 4 granted US patents, 22 granted non-US, 13 pending non-US; granted expire 2035-2037, pending could extend to 2045.","Lead WEE1 inhibitor APR-1051 in ACESOT-1051 Phase 1 trial for advanced solid tumors with gene alterations.","ATRN-119 RP2D set at 1,100 mg once daily in 2025; study closed to focus on APR-1051, combo approaches considered."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-102795","json":"https://secwatch.observer/filing/0001104659-26-102795.json","markdown":"https://secwatch.observer/filing/0001104659-26-102795.md","text":"https://secwatch.observer/filing/0001104659-26-102795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926102795/0001104659-26-102795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926102795/apre-20260828x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-28T12:35:32.037030+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}